NLRX1 and inflammatory bowel disease: Thus, identifying novel potential immunoregulatory targets such as NLRX1 that modulate tolerance and immune-mediated intestinal inflammation whose expression can be pharmacologically manipulated is significant for addressing an unmet medical need for safer, more effective, and faster IBD therapeutics.